MUSC Hollings Cancer Center researcher Jennifer Dahne was appointed director of Research Innovation and Integration within the Office of the Vice President for Research at the Medical University of South Carolina.
Triple-negative breast cancer is one of the most aggressive and treatment-resistant cancers. It grows quickly, spreads early, and lacks hormone receptors that make it treatable with targeted therapies. Even when patients initially respond to treatment, the cancer often returns and is more resistant.
